Gastrointestinal Motility Effects of GLP-1 Receptor Agonists.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and clinical implications without systematic search methodology or new human data
PubMed 40622491 · doi:10.1007/s11894-025-00995-3
What was done
This narrative review summarizes the physiologic effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on gastrointestinal motility, reviews their clinical implications, and identifies areas needing future investigation based on the published literature.
What was found
The abstract reports no numerical data or quantitative effect sizes. It qualitatively describes that GLP-1 RAs alter motility at all levels of the gastrointestinal tract, with delayed gastric emptying being the most prominent effect. These motility changes mediate key metabolic outcomes but also account for adverse effects such as nausea, vomiting, early satiety, dyspepsia, altered bowel habits, and a potential increase in periprocedural aspiration risk.
Why it matters
It highlights how the mechanistic motility effects of GLP-1 RAs underlie both their therapeutic profile and clinically relevant risks, including patient tolerability and perioperative aspiration hazards.
Limits
The publication is a narrative review presenting no original empirical data, sample size details, or systematic search and synthesis criteria. No quantitative risk comparisons across specific GLP-1 RA agents or dosages are provided in the abstract.
Cited by
- supports GLP-1 receptor agonists slow gastric motility and gastrointestinal transit.